



**UAMS News Bureau**

Office of Communications & Marketing  
4301 West Markham # 890  
Little Rock, AR 72205-7199

[uamshealth.com/news](http://uamshealth.com/news)

**News Release  
April 12, 2021**

**Media Contacts:**

**UAMS**

Leslie W. Taylor, 501-686-8998

Wireless phone: 501-951-7260

[leslie@uams.edu](mailto:leslie@uams.edu)

Yavonda Chase, 501-686-8994

Wireless phone: 501-416-0354

[yavonda@uams.edu](mailto:yavonda@uams.edu)

**Garvan Institute of Medical  
Research**

Dr. Viviane Richter,

+ 61 404 999 682

[v.richter@garvan.org.au](mailto:v.richter@garvan.org.au)

**Cancer DNA Blood Tests Validated  
By International Research Team**

Researchers independently validate industry-leading blood tests  
that can detect the DNA released by tumors

LITTLE ROCK — An international team today reports the findings of an independent assessment of five commercially-available assays for tumor DNA sequencing – a fast, cheap and less invasive method to diagnose and monitor cancer.

The researchers revealed that all assays could reliably detect so-called circulating tumor DNA (ctDNA) when it made up 0.5% of the total DNA in blood, a level of sensitivity that allows detection, genetic analysis and monitoring of late-stage and metastatic tumors.

[Published in the journal Nature Biotechnology](#), the study is a major milestone for the use of ctDNA assays as cancer diagnostics, outlining best-practice guidelines and uncovering key areas of future development.

[Nature's Behind the Paper channel](#) further explores aspects of how this research paper came to be and where subsequent research may lead.

The research was led by the Garvan Institute of Medical Research in Darlinghurst, Sydney, New South Wales; the FDA National Center for Toxicological Research in Jefferson, Arkansas; and the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences (UAMS). It forms part of the FDA-led Sequencing Quality Control Phase 2 project, which aims to develop standard protocols and quality control metrics for the use of next-generation sequencing in precision medicine, to make it a reality for patients.

“In order for ctDNA assays to be of benefit to patients in the clinic, they need to accurately and consistently detect cancer mutations across different labs and samples. Our study is the most comprehensive evaluation of analytical performance among ctDNA assays to date and represents a significant step forward in the field,” said first author Ira Deveson, Ph.D., from the Garvan Institute who led the independent evaluation.

### **Next-generation sequencing to monitor cancer DNA**

When cancer cells develop, they accumulate mutations in their DNA, fragments of which enter the bloodstream when cancer cells break down. Thanks to assays employing next-generation sequencing, these ctDNA fragments can now be detected in a patient's blood samples, which could be used to identify and monitor cancer as an alternative to more invasive tissue biopsies.

However, while ctDNA assays are already being adopted in precision oncology clinical trials, researchers and clinicians still lack a thorough understanding of how accurate current assays are, and which aspects of the technology still need to be improved. This knowledge helps define what applications ctDNA sequencing is suitable for and is needed before ctDNA sequencing can be implemented widely in clinical practice.

In their study, researchers from 12 participating laboratories in Europe, Asia and the United States evaluated the performance of current industry-leading ctDNA assays, from companies Roche Sequencing Solutions, Illumina, Integrated DNA Technologies, Burning Rock Dx and Thermo Fisher Scientific.

They tested the assays using synthetic experiments and mock-ctDNA reference samples. Their analysis revealed that all laboratories detected ctDNA mutations above 0.5% relative frequency (consistent with late-stage and metastatic tumors) with high sensitivity, precision and reproducibility using all participating assays. However, the assays detected lower levels of ctDNA (consistent with early-stage cancer or early signs of disease relapse) unreliably and inconsistently between different tests.

In their published paper, the researchers outline priorities for the future development of ctDNA assays, which they say will help advance the technology for clinical applications in monitoring tumor progression, response to therapy and cancer relapse.

“Our findings indicate that the participating ctDNA assays may be suitable for molecular stratification and profiling tumor evolution in advanced cancer patients. This should help clear a path for more advanced clinical trials of ctDNA assays,” said Donald Johann Jr.,

M.D., associate professor in the UAMS College of Medicine departments of Biomedical Informatics and Internal Medicine.

“Understanding the current assays’ detection limits was a crucial step towards a future where blood tests can be routinely used as a cancer screening tool. This critical study is a thorough analytical evaluation of ctDNA assays, which defined diagnostic limits, assessed reproducibility and identified key experimental variables that impact performance, and which has been called for by government, regulatory and clinical organizations,” said Joshua Xu, Ph.D., from the U.S. FDA National Center for Toxicological Research.

“Our independent performance analysis is a crucial mechanism to drive advances in next-generation sequencing approaches for their use in cancer detection and management. We expect it will help improve the tests’ sensitivity and reliability for diagnosing tumors at early stages,” said co-senior author Tim Mercer, Ph.D., associate professor from the Garvan Institute and the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland.

This research was supported by Australia’s National Health and Medical Research Council, a Broad Agency Announcement grant, the Medical Research Future Fund, Cancer Institute NSW and The Kinghorn Foundation.

The Garvan Institute of Medical Research is a leading multi-disciplinary biomedical research institute in Sydney. With 600 of the world’s brightest scientific minds working under one roof, collaborating across different areas of research and using the best technologies to investigate diseases, Garvan has revealed causes and treatments for diseases including diabetes, osteoporosis, cancer, immune deficiency and autoimmunity. [www.garvan.org.au](http://www.garvan.org.au)

UAMS is the state’s only health sciences university, with colleges of Medicine, Nursing, Pharmacy, Health Professions and Public Health; a graduate school; hospital; a main campus in Little Rock; a Northwest Arkansas regional campus in Fayetteville; a statewide network of regional campuses; and seven institutes: the Winthrop P. Rockefeller Cancer Institute, Jackson T. Stephens Spine & Neurosciences Institute, Harvey & Bernice Jones Eye Institute, Psychiatric Research Institute, Donald W. Reynolds Institute on Aging, Translational Research Institute and Institute for Digital Health & Innovation. UAMS includes UAMS Health, a statewide health system that encompasses all of UAMS’ clinical enterprise including its hospital, regional clinics and clinics it operates or staffs in cooperation with other providers. UAMS is the only adult Level 1 trauma center in the state. *U.S. News & World Report* named UAMS Medical Center the state’s Best Hospital; ranked its ear, nose and throat program among the top 50 nationwide; and named six areas as high performing — COPD, colon cancer surgery, heart failure, hip replacement, knee replacement and lung cancer surgery. UAMS has 2,876 students, 898 medical residents and four dental residents. It is the state’s largest public employer with more than 10,000 employees, including 1,200 physicians who provide care to patients at UAMS, its regional campuses, Arkansas Children’s Hospital, the VA Medical Center and Baptist Health. Visit [www.uams.edu](http://www.uams.edu) or [www.uamshealth.com](http://www.uamshealth.com). Find us on [Facebook](#), [Twitter](#), [YouTube](#) or [Instagram](#).

Like us, we're social:    

###